糖心原创

Przemek brings two decades of financial and investment experience focused on health, life sciences and technology across Europe and North America. Prior to joining 糖心原创, he built two investment organisations, led growth and buyout transactions with combined equity investment of $5 billion and was involved in over a dozen successful exits. Most recently, he served as the Managing Partner and CIO at a Swiss family office. Prior to that, he was the Managing Director and Head of European Private Equity at PSP Investments, a C$250 billion Canadian pension manager. Earlier in his career, he worked at CVC Capital Partners, EQT, and McKinsey & Company.

Przemek brings two decades of financial and investment experience focused on health, life sciences and technology across Europe and North America. Prior to joining 糖心原创, he built two investment organisations, led growth and buyout transactions with combined equity investment of $5 billion and was involved in over a dozen successful exits. Most recently, he served as the Managing Partner and CIO at a Swiss family office. Prior to that, he was the Managing Director and Head of European Private Equity at PSP Investments, a C$250 billion Canadian pension manager. Earlier in his career, he worked at CVC Capital Partners, EQT, and McKinsey & Company.

After completing her medical studies in Rome and a post-doctoral fellowship focused on cellular immunology at the National Cancer Institute in Bethesda (USA), Dr Alteri spent 7 years in drug discovery and 5 years in clinical safety at Ciba-Geigy/Novartis in Basel. She was involved in major projects that yielded important drugs such as Gleevec for myeloid leukaemia, Coartem for malaria and Reyataz for HIV-AIDS. In 1998 she joined Serono in Geneva where she led the Pharmacovigilance and Risk Management team. At Serono, Dr Alteri was instrumental in establishing the company鈥檚 pharmacovigilance processes, as well as implementing the entire portfolio鈥檚 risk management strategy.
In 2012 she joined the European Medicines Agency, where she was Head of the Safety and Efficacy Sector for one year, being later promoted to Head of the Human Medicines Evaluation Division, and then to Head of the Human Medicines R&D Support Division.
She was member of the EMA Executive Board from 2013 until she retired in 2020.
In this roles, Dr Alteri was part of many high impact EMA鈥檚 initiatives, from the transparency of clinical trial data to the development of regulatory science strategy to 2025.
Dr Alteri has been consulting for the Swiss regulatory agency (Swissmedic), and is currently member of the Scientific Committee and faculty of the Master Course in Drug R&D of the University of Geneva. Dr Alteri regularly gives lectures on various aspects of R&D at the Universities of Rome, Cattolica and LUISS, and at the European Course in Pharmaceutical Medicine at the University of Basel. Moreover, she is member of the CIOMS Working Group XIII (Real World Data/Real World Evidence), and the CIOMS. Working Group Education. Most recently, she has been appointed as Core Member of the Proposal Review Committee of Unitaid for a 3-year period.

Marie-Claire is a pioneering international expert in sustainability, law and public policy innovation. An award-winning expert jurist, executive and law professor specialised in corporate social responsibility, climate law and governance, sustainable trade and ethical investment rules, she is Visiting Chair of Sustainable Development Law and Policy at the University of Cambridge, and also serves as Senior Director of the global Centre for International Sustainable Development Law (CISDL). Having assisted in drafting the Paris Agreement, she has published over 24 books and 160 papers with world-class presses, edited five law journals and a Cambridge University Press book series, advised the United Nations and key countries, and helps purpose-led companies to advance the UN Sustainable Development Goals.